NCT00869986

A Study for Patients With Relapsing Remitting Multiple Sclerosis

A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 218 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis.

Conditions

• Relapsing Remitting Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	dirucotide	500mg, intravenous, every 6 months for 15 months
DRUG	placebo	intravenous, once every six months for 15 months

Timeline

• Start date: 2006-11-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2009-03-26
• Last updated: 2010-09-09

Locations

6 sites across 6 countries: Bulgaria, Poland, Russia, Serbia, Slovakia, Ukraine